The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer, GE team up on cancer research

Pfizer will send GE biopsy samples for analysis using its MultiOmyx tumor analysis technology and services in a bid to get an upper hand in drug development.

Hospira again shipping ketorolac but U.S. faces many drug shortages

Hospira recalled more than 60 lots of the pain reliever ketorolac tromethamine injection in January because of the potential for crystals in the 18 million vials that had been shipped in the U.S. and Singapore.

Pfizer's breast cancer-fighter Ibrance posts stellar second-line survival data

Last month, Pfizer announced it had cut short its PALOMA-3 trial thanks to impressive second-line data for new cancer-fighter Ibrance. And now, industry-watchers have a glimpse into those data, announced Saturday at ASCO.

Investors warm up to the idea of Pfizer snapping up GSK

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea.

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.

World Health Assembly passes resolution on vaccine pricing, transparency

The World Health Assembly passed a resolution Monday calling for improved vaccine pricing transparency and for more affordable vaccines, with more than 60 countries expressing support.

Happy anniversary? Taking stock at Pfizer, AstraZeneca one year after the mega-mega-deal collapse

One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.

GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze prices

When China said it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But as Bloomberg reports, the optimism may have been premature. Yes, the price caps won't affect most drugs beginning June 1. But foreign drugmakers are facing pressure to cut their prices voluntarily--more than ever.

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.

Hospira recalls solution marked as heparin

Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.